TauRx Therapeutics Management Ltd can confirm it has received formal confirmation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) that it requires some further information before a final determination on the suitability of hydromethylthionine mesylate (HMTM), as a potential oral treatment for Alzheimer’s disease, can be reached.
TauRx colleagues are in the process of working through the request in order to ensure answers are collated as expediently as is practicable.
The company is committed to working with the MHRA and other organisations as required, and further updates will be provided in due course.
MHRA response to HMTM Marketing Authorisation Application
